IMI2 JU

GPTKB entity

Properties (63)
Predicate Object
gptkbp:instanceOf Joint Undertaking
gptkbp:addresses health challenges
gptkbp:aimsTo improve health outcomes
reduce drug development costs
accelerate patient access to medicines
gptkbp:collaboratesWith gptkb:European_Commission
gptkbp:encourages innovation in healthcare
gptkbp:facilitates knowledge sharing
gptkbp:focusesOn public-private partnerships
gptkbp:funding research projects
gptkbp:hasCollaborationsWith public health organizations
gptkbp:hasFacility support innovative medicines research
gptkbp:hasFeature academic institutions
pharmaceutical industry
patient organizations
gptkbp:hasFunding industry contributions
EU_contributions
gptkbp:hasGoals enhance competitiveness
1.7 billion euros
gptkbp:hasImpactOn healthcare_systems
gptkbp:hasPartnershipsWith international organizations
gptkbp:hasProductLine IMI2_projects
https://www.w3.org/2000/01/rdf-schema#label IMI2 JU
gptkbp:isEvaluatedBy gptkb:European_Court_of_Auditors
independent experts
gptkbp:isFocusedOn rare diseases
chronic diseases
infectious diseases
gptkbp:isGovernedBy Governing_Board
gptkbp:isInvolvedIn medical research
patient engagement
personalized medicine
scientific research
disease prevention
digital health
vaccine development
drug safety
health technology assessment
translational medicine
healthcare education
healthcare_policy
clinical research networks
regulatory science
big data in healthcare
healthcare_delivery
healthcare_technology
healthcare_analytics
healthcare_innovation
gptkbp:isLocatedIn gptkb:Brussels
gptkbp:isManagedBy Executive Director
gptkbp:isPartOf gptkb:European_Innovation_Partnership
Horizon 2020
gptkbp:isRecognizedBy gptkb:European_Medicines_Agency
gptkbp:isSupportedBy pharmaceutical companies
research institutions
EU_member_states
gptkbp:operates European_Union_law
gptkbp:organizes workshops
gptkbp:promotes collaborative research
gptkbp:publishes annual reports
gptkbp:supports clinical trials
biomedical research
gptkbp:wasEstablishedIn 2014